Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Biotechs: Still Well Placed For More Gains

2018-02-20 seekingalpha
Big Pharma has to build out pipelines in new areas, and M&A is a compelling alternative. (719-3)

Why Gilead May Be Undervalued And May Fly High Again

2018-02-07 seekingalpha
Meanwhile, HCV sales have fallen off a cliff and can't get up without a ton of help from China, of which the company said nothing. (142-0)

Weighing Pros And Cons Of Celgene

2018-02-05 seekingalpha
The important, innovative biotech, CELG, has sold off again, closing the week a bit below the psychologically important $100 level. (112-0)

Perspective On Last Week's Carnage From Volatility Markets

2018-02-04 seekingalpha
Last week's pullback in equities likely marks the end of the era of intense calm from 2016 to 2017.

Biotech: The Gates Begin To Open

2018-01-26 seekingalpha
Biotech sector starts off the year strong with multiple acquisitions and partnerships, beginning to usher in the long-awaited M&A boom. (654-6)

Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid

2018-01-25 zacks
Celgene Corporation (CELG - Free Report) reported encouraging fourth-quarter 2017 results wherein both earnings and sales topped expectations. (93-1)

CAR-T Developers  Continue To Fly

2018-01-24 seekingalpha
Today, Celgene announced the acquisition of Juno Therapeutics for $9B and CAR-T stocks continued their trajectory higher. (31-4)

CAR-T Buying Bonanza, bluebird bio Is Next On The Acquisition Block

2018-01-24 seekingalpha
Two major deals in the CAR-T space have raised excitement and at the forefront comes bluebird bio with not only CAR-T tech but gene therapy tech as well. (37-0)

3 Small-Cap ETFs for Your Portfolio

2018-01-23 zacks
U.S. equity markets have been on a tear since President Donald Trump’s election, owing to his pro-growth policies. However, various concerns over geopolitics and political stability in the United States bother the markets (read: U.S. ETFs in Focus as Market Cap Hits $30 trillion). (73-2)

Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion

2018-01-23 zacks
Celgene Corporation (CELG - Free Report) announced that it will acquire Juno Therapeutics, Inc. (JUNO - Free Report) for $87 per share in cash, or a total of approximately $9 billion, net of cash and marketable securities acquired. The former already owns approximately 9.7% of outstanding shares of Juno. (93-0)

Bluebird Up on Buyout Speculation After Celgene/Juno Deal

2018-01-23 zacks
Buyout speculations related to Bluebird Bio, Inc. (BLUE - Free Report) are doing the rounds again. The rumors surfaced after biotech giant Celgene Corporation (CELG - Free Report) announced a $9 billion deal to buy Juno Therapeutics, Inc. (JUNO - Free Report) to add the latter’s CAR-T cancer therapy to its pipeline. (141-1)

bluebird bio (BLUE) Soars: Stock Adds 7.3% in Session

2018-01-18 zacks
bluebird bio, Inc.(BLUE - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 3.8% in the past one-month time frame. (54-0)

Analyzing The CAR-T Market: What Companies Have Performed Best And Will The Trend Continue In 2018?

2018-01-18 seekingalpha
The CAR-T market is red hot with 2 drug approvals, 1 major buyout (Kite) and a second potential major buyout (Juno) occurring in the last 6 months. (80-0)

Is Celgene (CELG) Looking to Take Over Juno Therapeutics?

2018-01-17 zacks
Per reports, biotech bigwig Celgene Corporation (CELG - Free Report) is looking to acquire smaller biotech Juno Therapeutics (JUNO - Free Report) . (93-0)

Can Litecoin Continue Its Run In 2018?

2018-01-15 seekingalpha
We feel that Litecoin is a safe bet, but that it may not have the highest returns in 2018.